Return to Patient Section

Medications not in widespread use

The medications listed in this section have been studied in clinical trials for eczema, but they are either not yet approved, may never be approved or are approved for uses other than eczema. Many have only been studied in adults. They are not currently in widespread use for eczema. Clinical trials are a protocol to evaluate the effectiveness and safety of medications. Drugs listed below may not be available to the public for several years, if ever.

Abrocitinib

Abrocitinib is an oral (pill) medication in a class known as Janus Kinase (JAK) inhibitors. It is included in our analysis based on one phase 2 clinical trial.

Apremilast

Apremilast is an oral (pill) medication that inhibits phosphodiesterase (PDE)-4. It is approved to treat psoriasis, but not eczema. It is included in our analysis based on one phase 2 clinical trial.

Baricitinib

Baricitinib is an oral (pill) medication in a class known as Janus Kinase (JAK) inhibitors. It is approved to treat arthritis, but not eczema. It is included in our analysis based on one phase 2 clinical trial.

Fevipiprant

Fevipiprant is an oral (pill) medication that blocks prostaglandin D2 receptor 2. It is included in our analysis based on one clinical trial published only in a clinical trials registry.

Fezakinumab

Fezakinumab is an injectable medication (biologic) that blocks Interleukin (IL)-22. It is included in our analysis based on one phase 2 clinical trial.

GBR 830

GBR 830 is an injectable medication (biologic) that blocks OX40. It is included in our analysis based on one phase 2 clinical trial.

Interferon gamma

Interferon gamma is an injectable medication that works by modifying the immune system. It is used in a number of different areas of medicine, but is not approved to treat eczema. It is included in our analysis based on two clinical trials.

IVIG

Intravenous immune globulin (IVIG) is given intravenously. It is used in a number of different areas of medicine, but is not approved to treat eczema. It is included in our analysis based on two clinical trials.

Lebrikizumab

Lebrikizumab is an injectable medication (biologic) that blocks Interleukin (IL)-13. It is included in our analysis based on one phase 2 clinical trial.

Nemolizumab

Nemolizumab is an injectable medication (biologic) that blocks Interleukin (IL)-31. It is included in our analysis based on two clinical trials.

Omalizumab

Omalizumab is an injectable medication (biologic) that blocks a molecule that is important for allergies called IgE. It is approved to treat urticaria (hives), but not eczema. It is included in our analysis based on one small clinical trial.

Tezepelumab

Tezepelumab is an injectable medication (biologic) that blocks Thymic Stromal Lymphoprotein (TSLP). It is included in our analysis based on one phase 2 clinical trial.

Tralokinumab

Tralokinumab is an injectable medication (biologic) that blocks Interleukin (IL)-13. It is included in our analysis based on one phase 2 clinical trial.

Upadacitinib

Upadacitinib is an oral (pill) medication in a class known as Janus Kinase (JAK) inhibitors. It is approved to treat arthritis, but not eczema. It is included in our analysis based on one phase 2 clinical trial.

Ustekinumab

Ustekinumab is an injectable medication (biologic) that blocks the interleukin 12/23 pathway. It is approved for use in psoriasis and other conditions, but not eczema. It is included in our review based on 2 clinical trials.

ZPL-3893787

ZPL-3893787 is an oral (pill) antihistamine medication. It is different from other antihistamines because it blocks a specific receptor called H4. It is included in our analysis based on a phase 2 clinical trial.